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• Dual loss of SDH and complex I is required for the metabolism of SDH mutant tumors 
• Loss of complex I impairs respiration in SDH-mutant cells 
• Loss of complex I induces reductive glutamine metabolism in SDH-mutant cells 
• Loss of complex I distinguishes SDH-mutant tumors versus SDH-mutant 
neurodegeneration 





Mutations in succinate dehydrogenase (SDH) are associated with tumor development and 
neurodegenerative diseases. Only in tumors, loss of SDH activity is accompanied with the 
loss of complex I activity. Yet, it remains unknown whether the metabolic phenotype of 
SDH mutant tumors is driven by loss of complex I function, and whether this contributes to 
the peculiarity of tumor development versus neurodegeneration. We addressed this 
question by decoupling loss of SDH and complex I activity in cancer cells and neurons. We 
found that sole loss of SDH activity was not sufficient to recapitulate the metabolic 
phenotype of SDH mutant tumors, because it failed to decrease mitochondrial respiration 
and to activate reductive glutamine metabolism. These metabolic phenotypes were only 
induced upon the additional loss of complex I activity. Thus, we show that complex I 
function defines the metabolic differences between SDH mutation associated tumors and 




Oncogenic transformations of cells are directly connected to changes in metabolism (Elia et al. 
2016). This is the case, because many tumor suppressors and oncogenes regulate metabolic 
enzymes (Elia et al. 2016). Thus, changes in metabolism are a consequence of the transformation 
process. Yet, metabolic changes can also be a cause of cellular transformation, because 
metabolites can regulate upstream signaling events by changing the activity state of oncogenes, 
tumor suppressors, and epigenetic regulators (Lorendeau et al. 2015). Examples of this latter 
class of transformation are mutations in TCA cycle enzymes (Nowicki and Gottlieb 2015). One 
of these enzymes is succinate dehydrogenase (SDH), which is mutated in a number of tumors 
such as paraganglioma and gastrointestinal stromal tumors (Evenepoel et al. 2015).  
SDH consists of four subunits. SDHA contains the catalytic binding pocket for succinate and 
produces FADH2 and fumarate within the TCA cycle. The electrons from FADH2 are then 
funneled via SDHB to SDHC and SDHD, which constitute the complex II function within the 
electron transport chain. Mutations in each individual SDH subunit result in the accumulation of 
succinate, which leads to a deregulation of signaling and epigenetic events and thus an oncogenic 
transformation (Morin et al. 2014; Nowicki and Gottlieb 2015). Beyond the accumulation of 
succinate it has been shown that SDH knockout and mutant cells rely on increased pyruvate 
 4
carboxylase (PC)-dependent aspartate production and reductive glutamine metabolism (Lussey-
Lepoutre et al. 2015; Cardaci et al. 2015; Saxena et al. 2016). Additionally, decreased 
mitochondrial respiration has been identified as a metabolic phenotype of SDH knockout and 
mutant cells (Rapizzi et al. 2015; Cardaci et al. 2015; Saxena et al. 2016). However, these latter 
alterations are also known consequences of complex I and III inhibition of the electron transport 
chain (Fendt et al. 2013a; Birsoy et al. 2015). Interestingly, SDH mutant tumors and SDH 
knockouts in cell lines show low or loss of complex I protein expression and activity (Favier et 
al. 2009; Cardaci et al. 2015). However it is unknown, whether the loss of SDH activity is 
sufficient to drive the metabolic phenotype of SDH mutant tumors or whether the accompanying 
loss of complex I activity also contributes to the specific metabolism of tumors associated with 
SDH mutations. Answering this question is of specific interest, because particular mutations in 
SDHA do not result in tumor development, but in neurodegenerative diseases such as Leigh 
syndrome, ataxia, and leukodystrophy (Hoekstra and Bayley 2013), and in these cases complex I 
activity is sustained (Burgeois et al. 1992; Bourgeron et al. 1995; Birch-Machin et al. 2000; 
Brockmann et al. 2002). Thus, complex I status in SDH mutant cells could support the disease 
prevalence of tumor development versus neurodegeneration.  
To address the role of complex I activity in SDH mutation related diseases, we characterized the 
metabolic phenotype of SDHB knockout cells and a cell line harboring the tumor-associated 
SDHA R589W mutation, and compared them to cells treated with SDHA or B inhibitors 
(resulting in sustain complex I activity, but loss of SDH activity), complex I inhibitor, and cells 
harboring the neurodegeneration-associated SDHA R451C mutation. We found that sole 
inhibition of SDHA or B was sufficient to increase succinate accumulation and PC-dependent 
metabolism in various cell lines. However, inhibition of SDHA or B failed to effectively reduce 
mitochondrial respiration and to increase reductive glutamine metabolism. The latter metabolic 
alterations could only be induced by an additional complex I inhibition. Hence, with this study 
we revealed that loss of complex I activity is important for the metabolic phenotype of tumors 
that are associated with SDH mutations. Moreover, we provide evidence that in 
neurodegenerative diseases, that are defined by SDH mutation (and sustained complex I 
activity), mitochondrial respiration occurs and results in a high succinate secretion flux that has 
the potential to negatively affect disease prognosis.  
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2. Materials and methods 
 
2.1 Cell culture conditions 
Since so far no cancer patients-derived immortalized cell lines carrying SDH mutations (e.g. 
paraganglioma, gastro-intestinal stromal tumors derived cell lines) have been described, we used 
pharmacological inhibitors of SDH on several cancer cell lines or cell lines genetically 
engineered to carry SDH mutations or knockouts.  
Hap1 cell line is a near-haploid human cell line derived from the male chronic myelogenous 
leukemia cell line (CML) KBM-7. Hap1 SDHA R589W cell line was generated with Haplogen 
company using a CRISPR/Cas9-based genome engineering strategy (Essletzbichler et al. 2014).  
Hap1 SDHA knockout (KO) + SDHA R451C overexpression and its control Hap1 SDHA KO + 
SDHA wildtype overexpression were generated as described in section 2.7. 
DU145 human prostate cancer cells were cultured in RPMI without pyruvate containing 10% 
dialyzed FBS and 1% penicilline/streptomycine. Huh7 human hepatocarcinoma cell line and 
HCT116 human colorectal carcinoma cell line were cultured in DMEM without pyruvate 
containing 10% dialyzed FBS and 1% penicilline/streptomycine. LUHMES mesencephalon 
neuronal cells were cultured and differentiated into dopaminergic neurons as described 
previously (Scholz et al. 2011). SDHB knockout (KO) mouse kidney cell lines, Hap1 cell lines 
and UOK262 human hereditary leiomyomatosis renal cell carcinoma (HLRCC) cell line were 
cultured in DMEM supplemented with 1 mM pyruvate, 10% dialyzed FBS and 1% 
penicilline/streptomycine. Additional nutrients (13C labeled or unlabeled), or drugs were added 
72h prior to cell harvest. The SDH inhibitor 3-nitropropionic acid (Sigma Aldrich #N5636) was 
applied at concentrations of 1 mM for LUHMES neurons and 5 mM for all other cell lines. The 
SDH inhibitor Atpenin A5 (Enzo life sciences #ALX-380-313) was applied at a concentration of 
500 nM. 3-NPA can be considered as an SDHA inhibitor, as it binds in the FAD binding pocket 
of SDH subunit A (Sun et al. 2005). Atpenin A5 can be considered as an SDHB inhibitor, as it 
binds in the ubiquinone binding pocket comprised of residues from SDH subunit B, C and D 
(Horsefield et al. 2006). Complex I inhibitor rotenone (Sigma Aldrich #R8875) was applied at 20 
ng ml−1. Glutaminase inhibitor CB-839 (Calithera) was applied at a concentration of 100 nM. 
The dose-dependent effect of drugs, rotenone on complex I as monitored by inhibition of oxygen 
consumption and 3-NPA and Atpenin A5 on SDH as monitored by succinate accumulation, were 
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carried out to determine the dose of drugs that trigger significant inhibitory effects. Rotenone at 
20 ng ml−1, Atpenin A5 at 500 nM and 3-NPA at 1-5 mM was sufficient to reach significant 
inhibitory effect of the drugs on complex I and SDH in cancer cell lines, respectively 
(Supplemental Figure S1A-E).  
 
2.2 13C tracer analysis 
All labeling experiments were performed in dialyzed serum for 72h. 13C6-glucose and 13C5-
glutamine tracers were purchased from Sigma-Aldrich. Metabolites for the subsequent mass 
spectrometry analysis were prepared by quenching the cells in liquid nitrogen followed by a cold 
two-phase methanol-water-chloroform extraction (Fendt et al. 2013a). Phase separation was 
achieved by centrifugation at 4 °C. The methanol-water phase containing polar metabolites was 
separated and dried using a vacuum concentrator. Dried metabolite samples were stored at -80 
°C. Polar metabolites were derivatized for 90 min at 37 °C with 7.5 µl of 20 mg ml−1 
methoxyamine in pyridine and subsequently for 60 min at 60 °C with 15 µl of N-(tert-
butyldimethylsilyl)-N-methyltrifluoroacetamide, with 1% tert-butyldimethylchlorosilane (Fendt 
et al. 2013b) (Sigma-Aldrich). Fatty acids were esterified with sulphuric acid/methanol for 180 
min at 60 °C and subsequently extracted with hexane. Isotopomer distributions and metabolite 
concentrations were measured with a 7890A GC system (Agilent Technologies) combined with a 
5975C Inert MS system (Agilent Technologies). 1 µl of sample was injected into a DB35MS 
column in splitless mode using an inlet temperature of 270 °C. The carrier gas was helium with a 
flow rate of 1 ml min−1. Upon injection, the GC oven was held at 100 °C for 3 min and then 
ramped to 300 °C with a gradient of 2.5 °C min−1 followed by a 5 min after run at 320 °C. For 
fatty acid samples, the oven was held at 80 °C for 1min and ramped with 5 °C min−1 to 300 °C. 
The MS system was operated under electron impact ionization at 70 eV and a mass range of 
100–650 amu was scanned. Isotopomer distributions were extracted from the raw ion 
chromatograms using a custom Matlab M-file, which applies consistent integration bounds and 
baseline correction to each ion (Young et al. 2008). In addition, we corrected for naturally 
occurring isotopes using the method of Fernandez et al. (Fernandez et al. 1996). Negative values 
were considered as zero. We corrected the mass spectra for potential metabolite contamination in 
a blank extraction. All labeling fractions were transformed to a natural abundance corrected mass 
distribution vector (MDV) (Buescher et al. 2015).  
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PC-dependent metabolism was assessed as described before (Christen et al. 2016). Additional 
correction from pyruvate m+3 was performed when labeling experiment were performed in 
presence of pyruvate 1 mM for SDHB KO and SDHA R589W cell lines.  
Metabolite concentrations were determined based on metabolite standard curve, the internal 
standards norvaline and glutarate, and cell numbers counted with a hemocytometer. Uptake and 
secretion rates of metabolite were determined based on the difference of metabolite 
concentrations in the media between 0h and 72h with or without drug treatment, normalized to 
the growth rates of cells. 
Fractional contribution of 5-13C-glutamine carbon source to fatty acid synthesis, D, and 
fractional new synthesis of fatty acids during time t, g(t), and total flux to fatty acid synthesis 
were estimated from the mass isotopomer distribution of palmitate based on isotopomer spectral 
analysis and palmitate concentrations as reported previously (Yoo et al. 2008; Fendt et al. 
2013a).  
Samples from LUHMES cells were analyzed using an Agilent 7890A GC coupled to an Agilent 
5975C inert XL Mass Selective Detector (Agilent Technologies). The gas chromatograph was 
equipped with a 30 m (I.D. 250 µm, film 0.25 µm) DB-35MS capillary column including 5 m 
DuraGuard column in front of the analytical column (Agilent J&W GC Column). Helium was 
used as carrier gas with a constant flow rate of 1 ml min−1. The GC oven temperature was held at 
100 °C for 2 min and increased to 300 °C at 10 °C min−1 and held for 4 min. The total run time 
was 26 min. The transfer line temperature was set to 280 °C. The MSD was operating under 
electron ionization at 70 eV. The MS source was held at 230 °C and the quadrupole at 150 °C. 
Mass spectra were recorded in the range of m/z 70 to 800. All GC-MS chromatograms were 
processed using MetaboliteDetector, v3.020151231Ra. The software package supports automatic 
deconvolution of all mass spectra. Compounds were annotated by retention index and mass 
spectrum (Hiller et al. 2009).  
 
2.3 13C metabolic flux model 
Intracellular fluxes were estimated using the Matlab based software Metran (Antoniewicz et al. 
2007; Young et al. 2008). Fluxes were modeled based on intracellular labeling of lactate, alanine, 
citrate, α-ketoglutarate, succinate, malate, aspartate, glutamate and glutamine from 13C6-glucose 
tracer. We assumed that the system is in steady state. Unpublished data confirm that there is no 
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significant difference in the labeling of polar metabolites after 24h or 72h confirming the steady 
state assumption. Moreover, we assumed that all CO2 in the system is unlabeled and that 
succinate has no orientation, because it is symmetrical. Additionally we assumed that any 
metabolite that is modeled in two different compartments is in equilibrium. The biomass fluxes 
were based on a previous publication and scaled by growth rate (Metallo et al. 2009). Entry of 
unlabeled glucose and acetyl-CoA precursors was assumed to be possible to account for fatty 
acid oxidation, glycogen stores, or entry of amino acids from the media. The pentose phosphate 
pathway flux was modeled as lower bound based on the flux to NTPs as described before (Lunt 
et al. 2015). Reductive glutamine metabolism was assumed to be cytosolic (Grassian et al. 2014). 
Glutamine to glutamate flux was calculated based on dynamic labeling data (Yuan et al. 2008; 
Buescher et al. 2015). 
 
2.4 Oxygen consumption rates 
Oxygen consumption was measured with an Oxytherm Clark electrode instrument (Hansatech). 
After a 72h treatment with 3-NPA 5 mM, Atpenin 500 nM, rotenone 20 ng ml−1, or oligomycin 
A 1 µM over 24h, cells were trypsinized and resuspended in fresh media with at least 2x106 cells 
for measurements. The oxygen consumption rate of cells in suspension was measured for 10 min 
at 37°C in the presence of the drugs. The slope of the linear range was used to calculate rates. 
Rates were calculated based on cell number counts using a hemocytometer. The ATP-coupled 
mitochondrial oxygen consumption rate is given by the difference between total oxygen 
consumption rates with or without SDH inhibitors (3-NPA, Atpenin A5) and oxygen 
consumption rates after oligomycin A treatment. 
 
2.5 Enzymatic activity of electron transport chain complexes 
The activity of citrate synthase and the individual complexes of the electron transport chain 
(complex I to complex IV) in cell lines was determined as described (Frazier and Thorburn 
2012), with minor modifications on mitochondrial enriched fractions of the wild type versus 
mutant cell lines. Briefly, enriched mitochondrial fractions were prepared from snap frozen cell 
pellets by homogenization with a glass homogenizer and motor-driven teflon plunger in 
homogenization buffer containing HEPES, EGTA and sucrose. Subsequently, enriched 
mitochondrial fractions were prepared by differential centrifugation at 4°C (600g for 10 min to 
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obtain crude mitochondrial fraction in the supernatant, and subsequent 144000g for 10 min for 
the enriched fraction in the resulting pellet). Except for complex III activity, pellets were 
resuspended in hypotonic buffer containing potassium phosphate and MgCl2. Citrate synthase 
and complex I-IV activities were determined by monitoring appearance or disappearance of 
specific substrates at specific wavelengths using spectrophotometry (e.g. oxidation of NADH for 
complex I activity at 340 nm in presence and absence of rotenone to evaluate complex I-specific 
activity, reduction of cytochrome c for complex III activity at 550 nm). A putative aspecific 
effect of pharmacological complex II inhibitors on other complexes activities was determined 
using the same technique. As such, the effect of 3-NPA (5 mM) and Atpenin (500 nM) on 
complex I, III and IV activities was determined by direct addition of the inhibitors to the cuvettes 
containing enriched mitochondrial fractions from DU145 cells. In order to draw general 
conclusions out of oxygen consumption rates (done on whole cells) and spectrophotometric 
enzymatic assays (done on mitochondrial extracts), we evaluated the mitochondrial abundance 
between cell lines by comparing citrate synthase activity on mitochondrial extracts with citrate 
synthase expression on whole cells (Supplemental Figure S2A-D). Since both measures provided 
similar results we normalized all measurements to protein and citrate synthase activity, to correct 
for mitochondrial abundance. 
 
2.6 Western blotting 
Cells were lysed in protein extraction buffer (25 mM Tris, 100 mM NaCl, 0.5% NP40, 0.5% 
deoxycholic acid, 5 mM EDTA, protease inhibitor cocktail (Sigma-Aldrich)). Aliquots of 50 µg 
of protein were separated on NuPAGE 4-12% denaturing Bis-Tris gels and transferred to 
nitrocellulose membranes (ThermoFisher Scientific). Antibodies used for western blot 
experiments were as follows, Oxphos complexes kit (Abcam ab110411), SDHA (ThermoFisher 
Scientific #459200), β-Actin (Sigma-Aldrich #A5441). The membranes were then incubated 
with horseradish peroxidase-linked mouse secondary antibodies (Cell Signaling Technology 






2.7 Genetic manipulations 
Hap1 SDHA R589W cell line was generated with Haplogen company using a CRISPR/Cas9-
based genome engineering strategy (Essletzbichler et al. 2014). SDHA knockout (KO) targeting 
crispr plasmids were generated by cloning the crispr guides targeting exon 10 of SDHA in the 
lentiviral crispr and guide expressing plasmid lentiCRISPR v2(Plasmid #52961). 2 guides 
(GGAGTTTGCCCCGAGGCGGT and GTGCCCGACCAAAGACAACC) were designed using 
the MIT crispr design website (http://crispr.mit.edu/).  
For SDHA R451C mutation and SDHA wt control, the SDHA ORF was bought as a gblock 
(Integrated DNA technologies) and cloned into the lentiviral pLVX-IRES-Hygromycin plasmid 
(Clontech, 632185) by gibson cloning using the NEbuilder kit (NEB, E5520S) (Table S1). 
Within the gblock the PAM sequences of the guides targeting SDHA were mutated with codon 
preservation. The SDHA R451C mutation was introduced by PCR (Table S1). Lentiviral 
particles for both the crispr KO vectors and the overexpression vectors were produced using a 
second generation lentiviral system using the psPAX2 packaging plasmid (Addgene Plasmid 
#12260) and the pMD2.G enveloppe plasmid (Addgene Plasmid #12259). Briefly, HEK293T 
cells were seeded at a density of 6x106 cells in a 10 cm2 dish with 10 ml of DMEM. After 24h 
incubation, cells were overlaid with the plasmids psPAX2 (packaging), pMD2.G (envelope) and 
PLVX-SDHA R451C or empty PLVX as control, together with optiMEM Lipofectamine 2000 
(ratio 1/3 total DNA/lipofectamine, Thermo Fisher Scientific). After 48h post-infection the virus 
was harvested, filtered, and stored at -80°C. Recipient cell lines at a confluence of 70% were 
incubated overnight with medium containing 1/2 diluted virus and 8 µg ml-1 final concentration 
of hexadimethrine bromide (Sigma-Aldrich). After 24h of recovery, infected cells were selected 
with 800 µg ml-1 hygromycin B (Gibco). Guide efficiency for KO was screened by measuring 
succinate accumulation in the cells, guide 1 was used in all experiments. Overexpression of 
SDHA wt and SDHA R451C were verified based on gene expression (supplemental Figure S3). 
 
2.8 qPCR 
Total RNA was isolated from 2 to 10 mg of snap-frozen mouse liver tissue using lysing matrix D 
tubes (M Biomedicals) and TRIzol Reagent (Thermo Fisher Scientific) according to the 
manufacturer’s protocol. Total RNA from cultured cell lines was isolated using the Purelink 
RNA Mini kit (Thermo Fisher Scientific). Single strand cDNA was synthetized from 1 µg of 
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total RNA using the qScript cDNA synthesis kit (Quantabio). Real-time quantitative PCR (RT-
qPCR) was performed on a Viia7 instrument (Applied Biosystems) using a platinum SYBR 
green qPCR supermix UDG (Thermo Fisher Scientific). The denaturation step was performed at 
95 °C for 5 min, and followed by PCR amplification of 40 cycles of denaturation at 95 °C for 15 
s and annealing and extension at 60 °C for 45 s. The standard cDNA was obtained using the PCR 
mastermix 2X (Thermo Fisher Scientific) according to the manufacturer’s protocol. The cDNA 
was loaded on a 1.5% agarose gel and run for 30 min at 135V. Afterwards, the cDNA was 
purified using the geneclean spin kit (Qbiogene) according to the manufacturer’s protocol, and 
dilutions were made (1 pg up to 1-10 pg). Primers used for analysis are listed below:  
Species Gene name Primer direction Sequence 
Human SDHA FW 5'-AGGAACCCGAGGTTTTCACT-3' 
  RV 5'-CCTACCACCACTGCATCAAA-3' 
Human Citrate Synthase FW 5'-TGCTTCCTCCACGAATTTGAAA-3' 
  RV 5'-CCACCATACATCATGTCCACAG-3' 
Mouse Citrate Synthase FW 5'-GGACAATTTTCCAACCAATCTGC-3' 
  RV 5'-TCGGTTCATTCCCTCTGCATA-3' 
Human RPL19 FW 5'-AGTATGCTCAGGCTTCAGAAGA-3' 
  RV 5'-ATTGGTCTCATTGGGGTCTAAC-3' 
Mouse RPL19 FW 5'-CAGGCATATGGGCATAGGGAA-3' 
  RV 5'-TGCCTTCAGCTTGTGGATGT-3' 
 
2.9 Statistical analysis 
Statistical analysis was performed for each experiment on n≥3 biological replicates using a two-
tailed paired t test with unequal variance for most of the experiments, except for enzymatic 
activities of electron transport chain complexes, where one-way ANOVA, Dunnett’s multiple 
comparison test (H) and unpaired Student’s t-test were used. *p<0.05, **p<0.01, ***p<0.001 
were used as symbols to represent significance levels. Either SEs or SDs were calculated as 








3.1 Paraganglioma-associated SDHA R589W mutation and SDHB knockout cells show a similar 
metabolic phenotype. 
Sympathetic paragangliomas and pheochromocytomas are rare neuroendocrine tumors that are 
mostly benign. About 10-20% of these tumors become malignant, and approximately half among 
those malignant tumors have been found to carry hereditary germline mutations in SDHB 
(Jimenez et al. 2013). SDHA mutations have been mainly described in sporadic forms of these 
tumors (Burnichon et al. 2016). SDHB knockout and mutant cell lines have been investigated 
extensively. Yet, it remains unknown whether the same metabolic phenotypes that are found in 
SDHB knockout or mutant cell lines also occur when paraganglioma-associated mutations are 
located in SDHA. To test this, we generated with Haplogen an isogenic human Hap1 cancer cell 
line with SDHA R589W mutation, which was the first discovered SDHA mutation to be 
associated with the onset of paraganglioma tumors in patients and leads to a SDHA and B 
protein loss in tumor tissue (Burnichon et al. 2010). We compared the metabolic alterations in 
this cell line to the previously described SDHB knockout cell line (Cardaci et al. 2015). To 
conclude on the metabolic phenotype of these cell lines, we measured the intracellular 
concentration alterations of 20 metabolites of central carbon metabolism using mass 
spectrometry (Figure 1A). Both SDHB knockout cells and SDHA R589W cells displayed very 
similar metabolite level alterations, which included succinate accumulation, and fumarate as well 
as malate depletion, which is consistent with an impairment of SDH catalytic activity. Moreover, 
citrate and aspartate levels were also decreased, which indicates a switch to reductive glutamine 
metabolism and an increased requirement for PC-dependent aspartate production (Fendt et al. 
2013a; Lussey-Lepoutre et al. 2015; Cardaci et al. 2015). To support our results from the 
metabolite concentration analysis, we next measured reductive glutamine and PC-dependent 
metabolism using 5-13C-glutamine and 13C6-glucose tracer analysis, respectively (Figure 1B-E). 
In line with our metabolomics results, we found that both SDHB knockout and SDHA R589W 
mutant cells showed increased reductive glutamine metabolism and PC-dependent metabolism.  
Next, we quantified mitochondrial respiration in SDHB knockout and SDHA R589W cells based 
on ATP-coupled oxygen consumption rates measured with a Clark electrode, and the activity of 
the respiratory chain complexes based on spectrophotometric enzymatic assays (Figure 1F-I). As 
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expected from literature (Cardaci et al. 2015), SDHB knockout resulted in decreased ATP-
coupled oxygen consumption rates and a loss of complex I, and II enzymatic activities. As 
expected from patient tissue (Burnichon et al. 2010), the insertion of the SDHA R589W mutation 
in Hap1 cells led to the loss of complex II activity. In addition, we found that SDHA R589W 
mutation in Hap1 cells showed a decreased cellular respiration and loss of complex I activity. 
Consequently we searched for the cause of the observed decreased complex I activity. Since 
SDHB knockout cells and paraganglioma patient samples were shown to have decreased 
expression of several electron transport chain complexes (Favier et al. 2009; Cardaci et al. 2015), 
we measured their protein expression in the Hap1 cells harboring the SDHA R589W mutation. 
We found that SDHA R589W cells showed an almost completely loss of complex I, SDHA, and 
SDHB protein expression (Figure 1J), which is consistent with decreased complexes activities. 
Taken together, we show that SDHB knockout and SDHA R589W mutant cells display a similar 
metabolic phenotype, which includes the loss of complex I activity. Thus, these data highlight 
the importance to assess which metabolic phenotype of SDH mutant tumors is driven by loss of 
SDH activity versus the accompanying loss of complex I activity.  
 
3.2 Inhibition of SDHA or B activity does not result in decreased cellular respiration or 
increased reductive glutamine metabolism. 
To test which metabolic phenotypes of tumors associated with SDH mutations are driven by loss 
of SDH versus complex I activity, we decoupled them using the SDHA inhibitor 3-
nitropropionic acid (3-NPA) and the SDHB inhibitor Atpenin A5, which both do not inhibit 
complex I. First, we verified that both inhibitors only targeted SDH function represented by 
complex II activity, but not complex I activity based on spectrophotometric enzymatic assays in 
DU145 human prostate cancer cells (Figure 2A). As expected, complex II activity, (representing 
SDH function) decreased upon treatment with 3-NPA or Atpenin A5. In line with the known 
specificity of the pharmacologic inhibitors (Miyadera et al. 2003; Sun et al. 2005), we found that 
complex I, III, and, IV activities were not significantly altered upon treatment with either 
inhibitor (Figure 2A).  
We next asked whether sole SDHA or B inhibition (without loss of complex I activity) is 
sufficient to induce the metabolic phenotype described for tumors associated with SDH 
mutations (succinate accumulation, increased reductive glutamine and pyruvate carboxylase 
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metabolism, as well as decreased cellular respiration). We determined the metabolic phenotype 
of cells upon treatment with 3-NPA and Atpenin A5 as described above. We found that sole 
SDHA or B inhibition was sufficient to induce succinate accumulation (>180 fold change to 
control for 3-NPA and >270 for Atpenin A5) (Figure 2B) and PC-dependent metabolism (Figure 
2C). Unexpectedly however, we discovered that reductive glutamine metabolism and most 
surprisingly cellular respiration were hardly altered upon SDHA or B inhibition (Figure 2D and 
E). After verifying this unexpected metabolic phenotype in additional cell lines (Huh7 liver 
cancer cell line and HCT116 colon carcinoma cell line) (Supplemental Figure S4A-D), we 
investigated whether the observed cellular respiration was coupled to mitochondrial ATP 
production. We found that ATP-coupled respiration was only marginally decreased or unaltered 
(Figure 2F). Thus, we concluded that loss of SDH activity was sufficient to induce succinate 
accumulation and to increase PC-dependent metabolism, but failed to induce reductive glutamine 
metabolism and to inhibit mitochondrial respiration. 
 
3.3 Dual loss of complex I and SDH activities recapitulate the metabolic phenotype of SDH 
mutant tumors. 
Next, we asked whether loss of complex I activity is necessary to induce reductive glutamine 
metabolism and loss of cellular respiration in cells with inhibited SDH activity. To achieve 
complex I loss of activity we treated cells with the complex I inhibitor rotenone on top of 3-NPA 
or Atpenin A5 treatment and measured reductive glutamine metabolism and cellular respiration. 
We found that the additional loss of complex I in cancer cells with inhibition of SDHA or B 
resulted in decreased cellular respiration and increased reductive glutamine metabolism (Figure 3 
A and B). In line with the observed increase in reductive glutamine metabolism, we found that 
rotenone treatment reduced the succinate secretion rate in 3-NPA or Atpenin A5 treated cells 
(Figure 3C). The comparison of the results from SDH and complex I inhibitor treated cells to 
only complex I inhibitor treated cells showed that the vast majority of the effects on reductive 
glutamine metabolism and cellular respiration were induced by complex I inhibition and not by a 
synergistic effect of SDH and complex I inhibition (Figure 3A and B). Thus, we concluded that 
dual loss of complex I and SDH activities is required to recapitulate the metabolic phenotype 
described for tumors associated with SDH mutations. 
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3.4 Succinate secretion flux is required for sustained cellular respiration upon SDHA inhibition. 
Dual loss of SDH and complex I activity is only observed in tumors associated with SDH 
mutations (Favier et al. 2009; Cardaci et al. 2015), but not in neurodegenerative diseases 
associated with SDH mutations (Burgeois et al. 1992; Bourgeron et al. 1995; Birch-Machin et al. 
2000; Brockmann et al. 2002). Thus, we next asked how respiration is sustained upon sole 
inhibition of SDH activity. To identify how cellular respiration is sustained upon loss of SDH 
activity we performed a 13C metabolic flux analysis in cells treated with and without 3-NPA 
(Figure 4A, Table S2). The estimated flux data confirmed our above-obtained results, which 
were based on 13C tracer analysis. In addition, we discovered that SDHA inhibition with 3-NPA 
significantly increased aspartate uptake, which is a metabolic alternative to PC-dependent de 
novo aspartate production. Moreover, we found that succinate accumulation upon SDHA 
inhibition was fueled mainly by glutamine metabolism, since glucose flux into the TCA cycle via 
pyruvate dehydrogenase was reduced by 2.8 fold, while glutamine anaplerosis was increased by 
4 fold. This significant glutamine flux into the TCA cycle upon SDHA inhibition was sustained 
by a consecutive succinate secretion flux, which indicates that the combination of glutamine 
anaplerosis and succinate secretion fluxes produces the redox equivalents needed to maintain 
cellular respiration. To test this hypothesis we treated cells with 3-NPA and the glutaminase 
inhibitor CB-839, which inhibits glutamine flux into the TCA cycle. Subsequently, we measured 
the succinate secretion flux and cellular respiration (Figure 4B, C). Supporting our hypothesis 
that glutamine flux into the TCA cycle combined with succinate secretion flux sustains 
mitochondrial respiration upon inhibition of SDH activity, we found that succinate secretion flux 
and the oxygen consumption rate were decreased upon treatment with the glutaminase inhibitor.  
Next, we tested whether it is possible to increase cellular respiration by inducing a succinate 
secretion flux. To do so we exploited another cancer associated TCA cycle enzyme alteration, 
namely the loss of fumarate hydratase (FH) in UOK262 cell lines. This alteration is found in 
specific forms of kidney cancer (human hereditary leiomyomatosis renal cell carcinoma) and 
leads to decreased cellular respiration (Yang et al. 2013; Nowicki and Gottlieb 2015). Thus, we 
hypothesized that treatment of fumarate hydratase null cells with 3-NPA initiates a succinate 
secretion flux and consequently cellular respiration. In agreement with this hypothesis, we found 
that 3-NPA treatment of fumarate hydratase null cells resulted in an increased succinate secretion 
flux (Figure 4D) and a two-fold increase in cellular respiration (Figure 4E). Notably, 3-NPA 
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treatment induced cellular respiration even reached 70% of the maximal possible cellular 
respiration, which was measured in UOK262 cells re-expressing fumarate hydratase (Figure 4E). 
Based on this data we concluded that cellular respiration is possible in cells with loss of SDH 
activity via a sustained succinate secretion flux. Moreover, this finding implies that decreased 
versus sustained cellular respiration is a major metabolic difference between tumors and 
neurodegenerative diseases associated with SDH mutations. 
 
3.5 SDHA inhibition in neurons and in cells with neurodegeneration-associated SDHA R451C 
mutation results in sustained cellular respiration  
To further support our hypothesis that deficiency in SDH activity associated with 
neurodegenerative diseases result in sustained cellular respiration, we tested whether SDHA 
inhibition in post-mitotic neuronal cells (differentiated LUHMES cell line) and overexpression 
of the neurodegeneration-associated SDHA R451C mutation in Hap1 cells results in succinate 
accumulation and sustained cellular respiration. In line with our hypothesis we found that SDHA 
inhibition by 3-NPA in differentiated LUHMES cells and overexpression of SDHA R451C in 
Hap1 cells induced succinate accumulation (Figure 5A and B), and resulted in sustained cellular 
respiration (Figure 5C and D).  
Next, we tested whether reductive glutamine metabolism was induced in differentiated 
LUHMES cells upon SDHA inhibition and in SDHA R451C overexpressing Hap1 cells. Since 
de novo fatty acids synthesis is limited in post-mitotic neurons, we investigated the 13C5-
glutamine contribution to citrate and malate. We specifically focused on the ratios of M+5/M+4 
citrate and M+3/M+4 malate from 13C5-glutamine, which are indicative of a change in reductive 
glutamine metabolism (Fendt et al. 2013a). We found that upon 3-NPA treatment both ratios 
were decreased (Figure 5E and F), indicating that upon SDHA inhibition differentiated 
LUHMES neurons did not induce reductive glutamine metabolism. To assess reductive 
glutamine metabolism in the SDHA R451C overexpressing Hap1 cells, we determined the 
contribution of 5-13C-glutamine to palmitate production as described above. In line with the 
results from LUHMES cells with inhibited SDHA activity, we found that SDHA R451C 
overexpression in Hap1 cells only marginally induces reductive glutamine metabolism (Figure 
5G). Thus, differently from tumor-associated SDH mutations, SDH inhibition in neurons and 
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SDHA mutations associated with neurodegenerative diseases resulted in sustained respiration 
and no significant induction of reductive glutamine metabolism. 
 
In conclusion, our findings suggest that the complex I activity together with the resulting 
metabolic alterations is a major difference of cells harboring SDH mutations associated with 
tumors versus SDH mutations associated with neurodegenerative diseases.  
 
4. Discussion 
Mutations in SDH are associated with rare tumors and neurodegenerative diseases. Here, we 
investigated whether loss of SDH activity is sufficient to induce the metabolic phenotype 
described for tumors with SDH mutation. We found that only a part of the tumor-associated 
metabolic phenotype is induced by loss of SDH activity. Full recapitulation of the described 
phenotype is only achieved by a dual loss of SDH and complex I activity. Our finding can 
consequently explain how SDH mutations can be associated with tumors, but also with 
neurodegenerative diseases, since the latter are defined by a sole decrease of SDH activity, but 
sustained complex I activity. 
 
SDH mutations found in tumors are coupled to an additional loss in complex I activity of the 
electron transport chain (Favier et al. 2009; Cardaci et al. 2015). However, loss of complex I 
activity is not observed for neurodegenerative diseases that are associated with SDH mutations 
(Burgeois et al. 1992; Bourgeron et al. 1995; Birch-Machin et al. 2000; Brockmann et al. 2002). 
A previous study found evidence that differential accumulation of ROS contributes to the cancer 
versus neurodegeneration association of SDH mutations (Guzy et al. 2008). Beyond this study 
we discovered that the metabolic phenotype of cells with SDH mutations associated with tumors 
or neurodegenerative diseases differs because of their differential complex I activity status. One 
can speculate that the additional loss of complex I activity, and thus the decrease in respiration 
(and increase in reductive glutamine metabolism) in tumors associated with SDH mutations is 
needed to allow redirecting carbon flow towards biomass precursor production. This speculation 
is in line with our finding that sole inhibition of SDH activity leads to almost complete 
proliferation inhibition in various cancer cell lines (data not shown). 
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Many neurodegenerative diseases are accompanied by an intra- and extracellular accumulation 
of succinate, which can repress the response of neurons to neurotransmitters such as 
acetylcholine (Andreev et al. 1986). Our finding that an inhibition of complex I in cells with loss 
of SDH activity reduces succinate intra- and extracellular accumulation, provides a mechanistic 
explanation for the observation that metformin, an antidiabetic drug which inhibits complex I 
(Fendt et al. 2013b), attenuates the progression of neurodegenerative diseases that are 
accompanied by succinate accumulation such as Huntington’s disease (Ma et al. 2007; Verwaest 
et al. 2011). Thus, it can be speculated that metformin treatment might also be beneficial to 
counteract disease progression in neurodegenerative diseases associated with SDH mutations. 
Additionally, it has been found that mTORC1 inhibition alleviates Leigh syndrome, which is 
frequently associated with SDH mutations (Johnson et al. 2013). mTORC1 is a known activator 
of glutamine flux into the TCA cycle (Csibi et al. 2013; Csibi et al. 2014). Thus, our finding that 
inhibition of glutaminase reduces succinate secretion flux in cells with impaired SDH function 
indicates that part of the beneficial effect of mTORC1 inhibition on Leigh syndrome symptoms 
can be explained by a reduction in glutamine-fueled succinate production and succinate secretion 
flux. Consequently, glutaminase inhibitors, which have been developed in the cancer research 
field (Elia et al. 2016), might have the potential to be a more targeted and effective therapy to 
inhibit the disease progression in Leigh syndrome patients with SDH mutations. 
 
In conclusion, our study shows that a dual loss of SDH and complex I function is necessary to 
explain the so far described metabolic phenotype of tumors associated with SDH mutations. 
Moreover, our study provides evidence that the obstacle how SDH mutations can be associated 
with both, tumors and neurodegeneration, can be explained by the additional loss of complex I 
activity in tumors (but not in neurodegerative diseases), which rewires metabolism presumably 
to allow proliferation. Consequently, our data suggest that reactivation of respiration in tumors 
associated with SDH mutations could inhibit their proliferation, while induction of complex I 
inhibition could be beneficial to counteract disease progression in patients with 
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Figure 1 Paraganglioma-associated SDHA R589W mutation and SDHB knockout cells 
show a similar metabolic phenotype 
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(A) Fold change of intracellular metabolite concentrations of SDHB knockout (KO) in mouse 
kidney and SDHA R589W Hap1 cell lines compared to the corresponding wild type cell lines. cl 
refers to the different clones of the generated cell lines. (B-C) Reductive glutamine metabolism 
based on the contribution of 5-13C-glutamine to palmitate. D values represent the fraction of 
newly synthesized palmitate that was produced from reductive glutamine metabolism in SDHB 
knockout (KO) mouse kidney and SDHA R589W Hap1 cell lines. Cells were incubated in 
medium containing 4 mM 5-13C-glutamine tracer for 72h. All 95% confidence intervals were ≤ 
3.8%. (D-E) PC-dependent metabolism in SDHB knockout (KO) mouse kidney and SDHA 
R589W Hap1 cell lines. PC-dependent metabolism was assessed based on the difference 
between malate and succinate M+3 divided by pyruvate M+3 from 13C6-glucose to correct for 
label dilution due to growth in presence of 1 mM pyruvate. (F-G) ATP-coupled respiration in 
SDHB knockout (KO) mouse kidney and SDHA R589W Hap1 cell lines. ATP-coupled 
respiration was assessed by the difference between total oxygen consumption rate and oxygen 
consumption rate in the presence of the ATP synthase inhibitor oligomycin A 1 µM. (H-I) 
Relative enzyme activities of electron transport chain complexes I to IV to the control in SDHB 
knockout (KO) mouse kidney and SDHA R589W Hap1 cell lines. Assays were performed on 
mitochondrial membrane fractions prepared from the cells. Complexes activities were 
normalized to the control, protein quantity and citrate synthase (CS) activity. Complex I specific 
activity was determined by subtracting the total complex I activity from the rotenone-sensitive 
complex I activity. (J) Expression levels of proteins of mitochondrial complexes I (NDUFB8 
subunit), II (SDHB and SDHA), III (Core 2 UQCRC2), IV (Cox II) and ATP synthase (ATP5A) 
in SDHA R589W Hap 1 cells compared to the wild type control cell line, as determined by 
western blot.  
Error bars depict either SD (B-G) or SE (H-I). Statistical analysis was performed for each 
experiment on n≥3 biological replicates using a two-tailed paired t test with unequal variance (B-
G), one-way ANOVA, Dunnett’s multiple comparison test (H) and unpaired Student’s t-test (I) 




Figure 2 Inhibition of SDHA or B activity does not result in decreased cellular respiration 
or increased reductive glutamine metabolism 
(A) Relative enzyme activities of electron transport chain complexes I to IV in DU145 prostate 
cancer cells. Assays were performed on cellular enriched mitochondrial fractions and in presence 
of SDH inhibitors 3-NPA 5 mM or Atpenin A5 500 nM. Complexes activities were normalized 
to the control, protein quantity, and citrate synthase (CS) activity. Complex I specific activity 
was determined by subtracting the total complex I activity from the rotenone-sensitive complex I 
activity. (B) Relative succinate levels in DU145 cells treated with SDH inhibitors 3-NPA or 
Atpenin A5. (C) PC-dependent metabolism in DU145 with 3-NPA or Atpenin A5. PC-dependent 
anaplerosis was assessed based on the difference between malate M+3 and succinate M+3 from 
13C6-glucose. (D) Reductive glutamine metabolism based on the contribution of 5-13C-glutamine 
to palmitate. D values represent the fraction of newly synthesized palmitate that was produced 
from reductive glutamine metabolism in DU145 cells treated with 3-NPA or Atpenin A5 upon 
incubation in medium containing 2 mM 5-13C-glutamine tracer for 72h. All 95% confidence 
intervals were ≤ 0.93%. (E) Cellular respiration measured in DU145 cells treated with 3-NPA or 
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Atpenin A5. (F) ATP-coupled respiration in DU145 treated with 3-NPA or Atpenin A5. ATP-
coupled respiration was assessed by the difference between total oxygen consumption rates and 
oxygen consumption rates in the presence of the ATP synthase inhibitor oligomycin A 1 µM.  
Error bars depict SE (A) or SD (B-F). Statistical analysis was performed for each experiment on 
n≥3 biological replicates using a two-tailed paired t test with unequal variance. *p<0.05, 




Figure 3 Dual loss of complex I and SDH activities recapitulates the metabolic phenotype of 
SDH mutant tumors  
(A) Reductive glutamine metabolism based on the contribution of 5-13C-glutamine to palmitate. 
D values represent the fraction of newly synthesized palmitate that was produced from reductive 
glutamine metabolism in DU145 prostate cancer cells treated with DMSO solvent control, 3-
NPA, or Atpenin A5 with or without complex I inhibitor rotenone. All confidence intervals were 
≤ 1.86%. (B) Cellular respiration measured in DU145 cells treated with DMSO solvent control, 
3-NPA or Atpenin A5 with or without complex I inhibitor rotenone. (C) Succinate secretion 
rates measured in DU145 with DMSO solvent control, 3-NPA, or Atpenin A5 with or without 
complex I inhibitor rotenone, based on succinate abundance in the media after 72h treatment 
with the drugs. In all experiments, cells were all treated over 72h with rotenone 20 ng ml−1, 3-
NPA 5 mM and Atpenin A5 500 nM.  
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Error bars depict SD. Statistical analysis was performed for each experiment on n≥3 biological 





Figure 4 Succinate secretion flux is required for sustained cellular respiration upon SDHA 
inhibition 
(A) Metabolic fluxes upon SDHA inhibition (3-NPA 5 mM) and in control (DMSO treated) 
condition in DU145 prostate cancer cells. Fluxes are normalized to the pyruvate entry into the 
mitochondria. Orange arrows indicate flux increases ≥ 2 fold in 3-NPA treated cells compared to 
control cells, blue arrows indicate flux decreases ≥ 2 fold in 3-NPA treated cells compared to 
control cells. Only selected fluxes are depicted (see Table S2 for the entirety of the estimated 
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fluxes). (B-C) Succinate secretion rates and cellular respiration in DU145 cells treated with 
DMSO (control condition) or 3-NPA (5 mM) in presence or absence of the glutaminase inhibitor 
CB-839 (100 nM). (D-E) Succinate secretion rates and cellular respiration in UOK262 kidney 
cancer cells, which are characterized by a loss of fumarate hydratase (FH) TCA cycle enzymes 
(FH KO), and in UOK262 control cells (FH WT) in which FH has been re-expressed, in presence 
and absence of 3-NPA (5 mM).  
Error bars depict SD. Statistical analysis was performed for each experiment on n≥3 biological 
replicates using a two-tailed paired t test with unequal variance. *p<0.05, **p<0.01, ***p<0.001 




Figure 5 Neurons with SDHA inhibition and cells with neurodegeneration-associated 
SDHA R451C mutation show sustained cellular respiration 
(A-B) Succinate levels in neurons (differentiated LUHMES cells) upon inhibition of SDHA with 
3-NPA 1 mM and in Hap1 SDHA knockout (KO) cells overexpressing the SDHA R451C 
mutation compared to control. (C-D) Cellular respiration in neurons (differentiated LUHMES 
cells) upon inhibition of SDHA with 3-NPA 1 mM and in Hap1 SDHA knockout (KO) cells 
overexpressing the SDHA R451C mutation compared to control. (E-F) Reductive versus 
oxidative glutamine metabolism (M+5 / M+4 labeling of citrate from 13C5-glutamine and M+3 / 
M+4 labeling of malate from 13C5-glutamine) in differentiated LUHMES cells. (G) Reductive 
glutamine metabolism based on the contribution of 5-13C-glutamine to palmitate. D values 
represent the fraction of newly synthesized palmitate that was produced from reductive 
glutamine metabolism in Hap1 SDHA KO cells overexpressing the SDHA R451C mutation and 
their control Hap1 SDHA KO overexpressing SDHA wt. All confidence intervals were ≤ 0.92%.  
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Error bars depict SD. Statistical analysis was performed for each experiment on n≥3 biological 




















Supplemental Figures S1-S4 and Tables T1-T2 
Lorendeau et al.: Dual loss of succinate dehydrogenase (SDH) and complex I activity is 




Figure S1 The SDH inhibitors 3-NPA and Atpenin A5 drastically increase succinate 
intracellular levels while reducing malate intracellular levels in DU145 cells. 
(A-B) Relative intracellular succinate and malate levels in DU145 cells upon treatment with the 
SDHA inhibitor 3-NPA. (C-D) Relative intracellular succinate and malate levels in DU145 cells 
upon treatment with the SDHB inhibitor Atpenin A5. (E) Cellular respiration (pmol/cell/h) 
measured in DU145 cells treated with the complex I inhibitor rotenone. Error bars depict SD. 
Statistical analysis was performed on (n≥3) independent biological replicates using a two-tailed 




Figure S2 Relative expression and activity levels of citrate synthase (CS) in SDHB KO and 
SDHA R589W mutant cell lines are similar. 
(A-B) Relative expression levels (mRNA) of citrate synthase (CS) in SDHB knockout (KO) 
mouse kidney cells and SDHA R589W Hap1 cells to control cells. (C-D) Relative CS enzymatic 
activity in mitochondrial fraction of SDHB KO mouse kidney cells and SDHA R589W Hap1 
cells to control cells. Error bars depict SE. Statistical analysis was performed on (n≥3) 












Figure S3 Relative expression of succinate dehydrogenase subunit A (SDHA) in Hap1 cell 
lines. 
Relative expression levels (mRNA) of succinate dehydrogenase subunit A (SDHA) in Hap1 wt, 
Hap1 SDHA KO cells overexpressing the SDHA R451C mutation and its control Hap1 SDHA 
KO SDHA wt overexpressing cell line. Error bars depict SD. Statistical analysis was performed 
on (n≥3) independent biological replicates using a two-tailed Student’s t-test with unequal 



















Figure S4 SDHA or B inhibition is not sufficient to induce reductive glutamine metabolism 
and decrease cellular respiration.  
(A-B) Reductive glutamine metabolism based on the contribution of 5-13C-glutamine to 
palmitate. D values represent the fraction of newly synthesized palmitate that was produced from 
reductive glutamine metabolism in Huh7 human hepatocarcinoma cells and in HCT116 human 
colorectal carcinoma cells treated with 3-NPA 5 mM or Atpenin A5 500nM upon incubation in 
medium containing 4 mM 5-13C-glutamine tracer for 72h. All 95 % confidence intervals were  
≤ 0.53% for ≤ 0.99% for HCT116. (C-D) Oxygen consumption rates (pmol/cell/h) measured in 
Huh7 and in HCT116 cells treated with 3-NPA 5 mM or Atpenin A5 500nM over 72h. Error bars 
depict SD. Statistical analysis was performed on (n≥3) independent biological replicates using a 
two-tailed Student’s t-test with unequal variance comparing pharmacological inhibition with 







































Red = point mutation CTG>TTG 


















Table 2 13C metabolic flux analysis in cells with and without 3-NPA treatment 
 
    DMSO 3-NPA 
    SSE = 56.0     SSE = 37.4     
    Expected SSE = [22.9 56.9] Expected SSE = [15.3 44.5] 
    (95% conf., 38 DOF)   (95% conf., 28 DOF)   
Metabolic Description Flux 95% conf. 95% conf. Flux 95% conf. 95% conf. 
reaction   [pmol/cell/h] min max [pmol/cell/h] min max 
R1             Gluc.x -> G6P                       0.601 0.5873 0.6158 0.812 0.7063 0.9175 
R2 net                G6P -> F6P                          0.6264 0.6264 0.642 0.8374 0.7281 0.9466 
R2 exch    G6P <-> F6P                         1.00E-07 0 Inf 0.5803 0 Inf 
R3      F6P -> DHAP + GAP                   0.6265 0.6113 0.6414 0.8374 0.7282 0.9466 
R4 net                       DHAP -> GAP                         0.6265 0.6113 0.6414 0.8374 0.7282 0.9466 
R4 exch                     DHAP <-> GAP                        0.2232 0 Inf 0.4433 0 Inf 
R5 net                        GAP -> 3PG                          1.25 1.223 1.283 1.675 1.456 1.893 
R5 exch                        GAP <-> 3PG                         0.3053 0 Inf 0.593 0 Inf 
R6                3PG -> Pyr.c                        1.246 1.216 1.276 1.673 1.455 1.892 
R7 net                    Pyr.c -> Lac                        1.177 1.148 1.205 1.657 1.44 1.875 
R7 exch                     Pyr.c <-> Lac                       0.0005601 0 Inf 0.1357 0 Inf 
R8                     Lac -> Lac.x                        1.177 1.148 1.205 1.657 1.44 1.875 
R9 net                       DHAP -> GLP                         0 0 0 -1.11E-16 0 0 
R9 exch                    DHAP <-> GLP                        1.66 0 Inf 0.2889 0 Inf 
R10 net                      GLP -> GLP.x                        0 0 0 -1.11E-16 0 0 
R10 exch                   GLP <-> GLP.x                       2.506 0 Inf 0.6478 0 Inf 
R11                       G6P -> 6PG                          0.005131 0 0.01493 0.001201 0 0.003553 
R12            6PG -> P5P + CO2                    0.005131 0 0.01493 0.001201 0 0.003553 
R13 net            P5P + P5P -> S7P + GAP              4.15E-05 -0.001943 0.003323 2.08E-07 -0.000467 0.000788 
R13 exch        P5P + P5P <-> S7P + GAP             1.00E-07 0 Inf 3.229 0 Inf 
R14 net             S7P + GAP -> F6P + E4P              4.15E-05 -0.001943 0.003323 2.08E-07 -0.000467 0.000788 
R14 exch           S7P + GAP <-> F6P + E4P             0.7496 0 Inf 0.1869 0 Inf 
R15 net             P5P + E4P -> F6P + GAP              4.15E-05 -0.001943 0.003323 2.08E-07 -0.000467 0.000788 
R15 exch      P5P + E4P <-> F6P + GAP             0.03613 0 0.1835 2.15E-05 0 0.9385 
R16            Pyr.m + CO2 -> Oac.m                0.0012 0.000916 0.001572 0.002394 0.001306 0.01991 
R17       Mal.m -> Pyr.m + CO2                0.00764 0.007059 0.01568 0.001821 0.0009102 0.07655 
R18 Pyr.m -> AcCoA.m + CO2  0.02598 0.02364 0.02998 0.009331 0.007259 0.01208 
R19          AcCoA.m + Oac.m -> Cit.m           0.02598 0.02338 0.02948 0.009332 0.006997 0.01213 
R20              Cit.m -> Akg.m + CO2                0.02047 0.01851 0.02361 0.005402 0.003422 0.007986 
R21  Akg.m -> Suc + CO2        0.03014 0.02754 0.04081 0.04387 0.03798 0.0498 
R22 net              Suc -> Fum.m               0.03012 0.0275 0.0408 -0.0002563 -0.004133 0.002954 




  DMSO 3-NPA 
Metabolic Description Flux 95% conf. 95% conf. Flux 95% conf. 95% conf. 
reaction   [pmol/cell/h] min max [pmol/cell/h] min max 
R24 net      Mal.m -> Oac.m            0.02478 -0.00326 0.03588 0.01022 -0.008623 0.032 
R24 exch       Mal.m <-> Oac.m           0.1353 0.02613 Inf 0.01378 0 Inf 
R25          Cit.m -> AcCoA.c + Oac.c            0.005514 0.00388 0.007111 0.003929 0.002891 0.004972 
R26           Cit.c -> AcCoA.c + Oac.c            0.002395 0.001956 0.002861 0.001389 0.001122 0.001597 
R27 net                 Fum.c -> Mal.c                      892.2 0 > 4.653e+06 1.01E-07 0 0.09592 
R27 exch              Fum.c <-> Mal.c                     654.4 0 Inf 0.004953 0 0.1479 
R28 net                    Mal.c -> Oac.c                      892.2 -0.002296 > 4.182e+05 -0.01229 -0.1065 -0.004283 
R28 exch  Mal.c <-> Oac.c                     1.00E-07 0 Inf 0.001687 0 Inf 
R29 net               Oac.c -> Asp.c                      892.2 -0.01308 > 3.875e+05            -0.006975 -0.02804 0.03918 
R29 exch             Oac.c <-> Asp.c                     1.00E-07 0 Inf 1.00E-07 0 Inf 
R30      Asp.c -> Fum.c                      892.2 0 > 4.653e+06 1.01E-07 0 0.09592 
R31                 AcCoA.c -> FA                       0.007909 0.006342 0.009468 0.005318 0.004313 0.006356 
R32 net           Pyr.m -> Ala                        0.01271 0.0115 0.01391 0.002799 0.002186 0.003411 
R32 exch              Pyr.m <-> Ala                       0.3269 0 Inf               0.2426 0 Inf 
R33 net                Oac.m -> Asp.m                      -4.44E-16 -0.0281 0.02339 0.003278 -0.01371 0.04433 
R33 exch     Oac.m <-> Asp.m                     0.2243 0 Inf              1.00E-07 0 Inf 
R34                 Gln.x -> Gln                        0.0385 0.0352 0.04572 0.04725 0.04132 0.05316 
R35 net            Gln -> Glu                          0.03719 0.03382 0.04443 0.04695 0.041 0.05291 
R35 exch                        Gln <-> Glu                         0.07891 0.03893 0.206 0.6956 0.03234 Inf 
R36                  Glu -> Glu.x                        0.02323 0.01973 0.02628 0.006691 0.0003776 0.01302 
R37 net           Glu -> Akg.m               0.009672 0.00844 0.0176 0.03847 0.03267 0.04443 
R37 exch Glu <-> Akg.m               2.923 0.8564 Inf 0.2034 0.04485 Inf 
R38 net                    Glu -> Akg.c                        0.002395 0.001956 0.002861 0.001389 0.001122 0.001597 
R38 exch                 Glu <-> Akg.c                       0.6509 0 Inf 1.838 0 Inf 
R39       Akg.c + CO2 -> Cit.c                0.002395 0.001956 0.002861 0.001389 0.001122 0.001597 
R40 Asp.c -> Biomass                    0.003108 0.002501 0.003703 0.0008 0.0006434 0.000956 
R41                   Glu -> Biomass                      0.001903 0.00153 0.002273 0.0003993 0.0003215 0.000478 
R42                    Ala -> Biomass                      0.003603 0.002898 0.004307 0.0008999 0.0007236 0.001076 
R43           Gln -> Biomass                      0.001301 0.001046 0.001555 0.0002996 0.0002427 0.000358 
R44              Asp.c -> NTP + CO2                  0.002505 0.002015 0.002987 0.0006 0.0004825 0.000717 
R45                        P5P -> NTP                          0.005007 0.004027 0.005983 0.0012 0.0009647 0.001435 
R46                   3PG -> Ser                          0.006707 0.005394 0.00802 0.0013 0.001045 0.001555 
R47                      Ala -> Ala.x                        0.009107 0.008127 0.01008 0.001899 0.001312 0.002487 








    DMSO 3-NPA 
Metabolic Description Flux 95% conf. 95% conf. Flux 95% conf. 95% conf. 
reaction   [pmol/cell/h] min max [pmol/cell/h] min max 
R48     Asp.x -> Asp.c                      1.00E-07 0 0.001189 0.005097 0.001435 0.02341 
R49             Pyr.c -> Pyr.x                      0.03758 0.02799 0.04715 0.003499 0.001931 0.005067 
R50                Suc -> Suc.x                        1.28E-05 0 0.000403 0.04413 0.03763 0.0509 
R51 net               Pyr.c -> Pyr.m                      0.03225 0.0271 0.0343 0.0127 -0.04505 0.01573 
R51 exch            Pyr.c <-> Pyr.m                     1.00E-07 0 0.0384 1.00E-07 0 0.736 
R52           0*Pyr.c -> Pyr.mnt                  1 0 1 0.3101 0 1 
R53 0*Pyr.m -> Pyr.mnt                  1.00E-07 0 1 0.6899 0 1 
R54             Pyr.mnt -> Pyr.fix                  1 1 1 1 1 1 
R55                0*Cit.c -> Cit.mnt                  0.1066 0.08387 0.1166 0.398 0.3087 0.4852 
R56  0*Cit.m -> Cit.mnt                  0.8934 0.8834 0.9161 0.602 0.5148 0.6913 
R57             Cit.mnt -> Cit.fix                  1 1 1 1 1 1 
R58             0*Fum.c -> Fum.mnt                  0.701 0 1 0.2817 0 1 
R59                0*Fum.m -> Fum.mnt                  0.299 0 1 0.7183 0 1 
R60               Fum.mnt -> Fum.fix                  1 1 1 1 1 1 
R61                0*Akg.c -> Akg.mnt                  1 0 1 0.3057 0 1 
R62                 0*Akg.m -> Akg.mnt                  1.00E-07 0 1 0.6943 0 1 
R63              Akg.mnt -> Akg.fix                  1 1 1 1 1 1 
R64 net            Mal.c -> Mal.m                      0.002296 -0.02593 0.01811 0.01229 -0.002543 0.09538 
R64 exch         Mal.c <-> Mal.m                     0.01674 0 0.03743 56.12 0 Inf 
R65              0*Mal.c -> Mal.mnt                  0.7169 0.222 1 1 0 1 
R66              0*Mal.m -> Mal.mnt                  0.2831 0 0.778 1.01E-07 0 1 
R67      Mal.mnt -> Mal.fix                  1 1 1 1 1 1 
R68 net                 Asp.c -> Asp.m                      2.36E-16 -0.02339 0.0281 -0.003278 -0.04433 0.01371 
R68 exch            Asp.c <-> Asp.m                     1.00E-07 0 0.01865 0.6969 0 Inf 
R69         0*Asp.c -> Asp.mnt                  1 0.328 1 0.9864 0 1 
R70       0*Asp.m -> Asp.mnt                  1.00E-07 0 0.672 0.01364 0 1 
R71  Asp.mnt -> Asp.fix                  1 1 1 1 1 1 
R72 UnlabeledAcCoA.x -> AcCoA.m 1.00E-07 0 0.000622 1.00E-07 0 0.000239 
R73            UnlabeledC.x -> G6P                 0.03056 0.02623 0.03334 0.02655 0 0.03241 
 
 
 
 
 
 
 
 
